Acinetobacter Infections - Pipeline Review, H2 2015

Publisher Name :
Date: 30-Nov-2015
No. of pages: 114
Inquire Before Buying

Global Markets Direct's, ‘Acinetobacter Infections - Pipeline Review, H2 2015', provides an overview of the Acinetobacter Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acinetobacter Infections

  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in the therapeutics development for Acinetobacter Infections and enlists all their major and minor projects

  • The report summarizes all the dormant and discontinued pipeline projects

  • A review of the Acinetobacter Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • A detailed assessment of monotherapy and combination therapy pipeline projects

  • Coverage of the Acinetobacter Infections pipeline on the basis of target, MoA, route of administration and molecule type

  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Identify and understand important and diverse types of therapeutics under development for Acinetobacter Infections

  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

  • Devise corrective measures for pipeline projects by understanding Acinetobacter Infections pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Acinetobacter Infections - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Acinetobacter Infections Overview 11
Therapeutics Development 12
Pipeline Products for Acinetobacter Infections - Overview 12
Pipeline Products for Acinetobacter Infections - Comparative Analysis 13
Acinetobacter Infections - Therapeutics under Development by Companies 14
Acinetobacter Infections - Therapeutics under Investigation by Universities/Institutes 16
Acinetobacter Infections - Pipeline Products Glance 17
Clinical Stage Products 17
Early Stage Products 18
Acinetobacter Infections - Products under Development by Companies 19
Acinetobacter Infections - Products under Investigation by Universities/Institutes 21
Acinetobacter Infections - Companies Involved in Therapeutics Development 22
Achaogen Inc. 22
Adenium Biotech ApS 23
AmpliPhi Biosciences Corporation 24
Aridis Pharmaceuticals LLC 25
AstraZeneca Plc 26
AvidBiotics Corp. 27
Emergent BioSolutions Inc. 28
Evaxion Biotech 29
F. Hoffmann-La Roche Ltd. 30
FAB Pharma 31
FOB Synthesis, Inc. 32
LegoChem Biosciences, Inc 33
Melinta Therapeutics, Inc 34
Microbiotix, Inc. 35
MicuRx Pharmaceuticals, Inc. 36
Nosopharm SAS 37
Novan, Inc. 38
Omnia Molecular Ltd. 39
Pfizer Inc. 40
Phylogica Limited 41
Sarepta Therapeutics, Inc. 42
Sealife PHARMA GMBH 43
Shionogi & Co., Ltd. 44
Synthetic Biologics, Inc. 45
Techulon, Inc. 46
Tetraphase Pharmaceuticals Inc. 47
Trana Discovery, Inc. 48
Vaxdyn, S.L. 49
Acinetobacter Infections - Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Combination Products 51
Assessment by Target 52
Assessment by Mechanism of Action 54
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 60
A-3APO - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
AA-139 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ACHN-975 Prodrug - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Acinetobacter vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Antisense Oligonucleotide for Acinetobacter Baumannii Infections - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
AR-401 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
AvR2-V10 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Biologics for Acinetobacter Baumannii - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Cephalosporin + Beta-Lactamase Inhibitor - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
EV-035 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Fab-001 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
FSI-1671 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
FSI-1686 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
GN-4474 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
LCB-100200 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
MBX-1162 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
MDN-0057 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
MRX-V - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
NOSO-95179 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
NVN-1000 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
OM-011818 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
pneumonia vaccine - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
RX-05 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
RXP-873 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
S-649266 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
SLP-0905 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Small Molecule for Acinetobacter baumannii Infections - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Small Molecule to Target Bacterial Cell Membrane for Acinetobacter Infections - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Small Molecules for Acinetobacter Infections - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Small Molecules for Multi-Drug Resistant Bacterial Infections - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Small Molecules to Inhibit NDH-1 for Acinetobacter baumannii Infections - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
SYN-001 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
TP-6076 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
VXD-001 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
VXD-003 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Acinetobacter Infections - Recent Pipeline Updates 107
Acinetobacter Infections - Dormant Projects 112
Appendix 113
Methodology 113
Coverage 113
Secondary Research 113
Primary Research 113
Expert Panel Validation 113
Contact Us 113
Disclaimer 114

List of Tables

Number of Products under Development for Acinetobacter Infections, H2 2015 12
Number of Products under Development for Acinetobacter Infections - Comparative Analysis, H2 2015 13
Number of Products under Development by Companies, H2 2015 15
Number of Products under Investigation by Universities/Institutes, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Development, H2 2015 18
Products under Development by Companies, H2 2015 19
Products under Development by Companies, H2 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2015 21
Acinetobacter Infections - Pipeline by Achaogen Inc., H2 2015 22
Acinetobacter Infections - Pipeline by Adenium Biotech ApS, H2 2015 23
Acinetobacter Infections - Pipeline by AmpliPhi Biosciences Corporation, H2 2015 24
Acinetobacter Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2015 25
Acinetobacter Infections - Pipeline by AstraZeneca Plc, H2 2015 26
Acinetobacter Infections - Pipeline by AvidBiotics Corp., H2 2015 27
Acinetobacter Infections - Pipeline by Emergent BioSolutions Inc., H2 2015 28
Acinetobacter Infections - Pipeline by Evaxion Biotech, H2 2015 29
Acinetobacter Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 30
Acinetobacter Infections - Pipeline by FAB Pharma, H2 2015 31
Acinetobacter Infections - Pipeline by FOB Synthesis, Inc., H2 2015 32
Acinetobacter Infections - Pipeline by LegoChem Biosciences, Inc, H2 2015 33
Acinetobacter Infections - Pipeline by Melinta Therapeutics, Inc, H2 2015 34
Acinetobacter Infections - Pipeline by Microbiotix, Inc., H2 2015 35
Acinetobacter Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2015 36
Acinetobacter Infections - Pipeline by Nosopharm SAS, H2 2015 37
Acinetobacter Infections - Pipeline by Novan, Inc., H2 2015 38
Acinetobacter Infections - Pipeline by Omnia Molecular Ltd., H2 2015 39
Acinetobacter Infections - Pipeline by Pfizer Inc., H2 2015 40
Acinetobacter Infections - Pipeline by Phylogica Limited, H2 2015 41
Acinetobacter Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2015 42
Acinetobacter Infections - Pipeline by Sealife PHARMA GMBH, H2 2015 43
Acinetobacter Infections - Pipeline by Shionogi & Co., Ltd., H2 2015 44
Acinetobacter Infections - Pipeline by Synthetic Biologics, Inc., H2 2015 45
Acinetobacter Infections - Pipeline by Techulon, Inc., H2 2015 46
Acinetobacter Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2015 47
Acinetobacter Infections - Pipeline by Trana Discovery, Inc., H2 2015 48
Acinetobacter Infections - Pipeline by Vaxdyn, S.L., H2 2015 49
Assessment by Monotherapy Products, H2 2015 50
Assessment by Combination Products, H2 2015 51
Number of Products by Stage and Target, H2 2015 53
Number of Products by Stage and Mechanism of Action, H2 2015 55
Number of Products by Stage and Route of Administration, H2 2015 57
Number of Products by Stage and Molecule Type, H2 2015 59
Acinetobacter Infections Therapeutics - Recent Pipeline Updates, H2 2015 107
Acinetobacter Infections - Dormant Projects, H2 2015 112

List of Figures

Number of Products under Development for Acinetobacter Infections, H2 2015 12
Number of Products under Development for Acinetobacter Infections - Comparative Analysis, H2 2015 13
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 16
Comparative Analysis by Early Stage Products, H2 2015 18
Assessment by Monotherapy Products, H2 2015 50
Number of Products by Top 10 Targets, H2 2015 52
Number of Products by Stage and Top 10 Targets, H2 2015 52
Number of Products by Top 10 Mechanism of Actions, H2 2015 54
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 54
Number of Products by Routes of Administration, H2 2015 56
Number of Products by Stage and Routes of Administration, H2 2015 56
Number of Products by Molecule Types, H2 2015 58
Number of Products by Stage and Molecule Types, H2 2015 58
  • Yellow Fever - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 52
    Yellow Fever - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Yellow Fever - Pipeline Review, H2 2018, provides an overview of the Yellow Fever (Infectious Disease) pipeline landscape. Yellow fever is an acute systemic illness (hemorrhagic fever) caused by the Flavivirus. It is spread by mosquitoes. Symptoms include irregular heartbeats, bleeding, vomiting, coma, delirium, fever, he......
  • Measles - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 39
    Measles - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Measles - Pipeline Review, H2 2018, provides an overview of the Measles (Infectious Disease) pipeline landscape. Measles is a highly infectious viral disease. The virus lives in the mucus of the nose and throat of people with this infection. Physical contact, coughing and sneezing can spread the infection. Symptoms of measles ......
  • Japanese Encephalitis - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 48
    Japanese Encephalitis - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Japanese Encephalitis - Pipeline Review, H2 2018, provides an overview of the Japanese Encephalitis (Infectious Disease) pipeline landscape. Japanese encephalitis is a viral disease that infects animals and humans. It is caused by a flavivirus that affects the membranes around the brain. It is transmitted by mosq......
  • Hepatitis D - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 69
    Hepatitis D - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis D - Pipeline Review, H2 2018, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape. Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pai......
  • Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 84
    Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2018, provides an overview of the Chagas Disease (American Trypanosomiasis) (Infectious Disease) pipeline landscape. Chagas disease or American Trypanosomiasis is a vector-borne anthropozoonosis caused by the protozoan parasite Tr......
  • Rabies - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 77
    Rabies - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rabies - Pipeline Review, H2 2018, provides an overview of the Rabies (Infectious Disease) pipeline landscape. Rabies is a deadly virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. Symptoms include loss of feeling in an area of the body, loss of muscle function, s......
  • Hepatitis A - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 27
    Hepatitis A - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis A - Pipeline Review, H2 2018, provides an overview of the Hepatitis A (Infectious Disease) pipeline landscape. Hepatitis A is inflammation of the liver caused by hepatitis A virus. Symptoms include fatigue, nausea and vomiting, inflammation of the liver, loss of appetite, dark urine, muscle pain and yellowing of ......
  • Haemophilus influenzae Type B Infections - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 69
    Haemophilus influenzae Type B Infections - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Haemophilus influenzae Type B Infections - Pipeline Review, H2 2018, provides an overview of the Haemophilus influenzae Type B Infections (Infectious Disease) pipeline landscape. Haemophilus influenzae type B (Hib) is a bacterium that causes a life-threatening infection that can lead to serious......
  • Rotavirus Infections - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 51
    Rotavirus Infections - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rotavirus Infections - Pipeline Review, H2 2018, provides an overview of the Rotavirus Infections (Infectious Disease) pipeline landscape. Rotavirus is a virus that infects the bowels. Rotavirus is the most common cause of severe diarrhea among infants and children. Transmission of rotavirus most often occurs thro......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs